Related Experiment Video
Updated: Sep 26, 2025
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.0K
Digital Solutions to Diagnose and Manage Postbariatric Hypoglycemia
Katja A Schönenberger1,2, Luca Cossu3, Francesco Prendin3
1Department of Diabetes, Endocrinology, Nutritional Medicine and Metabolism, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Frontiers in Nutrition
|April 25, 2022
Summary
Postbariatric hypoglycemia (PBH) management can be improved with digital tools. These technologies offer data-driven insights for better glucose control and quality of life for patients.
Area of Science:
- Metabolic complications
- Endocrinology
- Digital health
Background:
- Postbariatric hypoglycemia (PBH) is a growing concern after bariatric surgery.
- It involves low blood glucose levels post-meal, especially with fast-acting carbohydrates.
- Current nutritional management is challenging for patients and providers.
Purpose of the Study:
- To explore the potential of emerging digital technologies in managing PBH.
- To identify how data integration and AI can improve glucose control and patient outcomes.
- To address challenges and trade-offs associated with digital health solutions for PBH.
Main Methods:
- Review of emerging digital technologies for PBH management.
- Discussion of data integration (food analysis, glucose monitoring) and AI applications.
- Analysis of challenges including user burden, data privacy, and regulatory compliance.
Main Results:
- Digital tools like automated food analysis and continuous glucose monitoring offer improved data access.
- AI can process multi-dimensional data for prediction algorithms and decision support.
- Challenges include balancing data quality/quantity with user burden and ensuring regulatory compliance.
Conclusions:
- Digital innovations hold significant promise for improving PBH management.
- Addressing trade-offs in data, privacy, and regulation is crucial for successful implementation.
- These solutions can enhance glucose control, safety, and quality of life for PBH patients.
Related Concept Videos
01:15Hypoglycemia and Glucagon
362
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
362
01:14SBAR II: Application of SBAR
4.8K
SBAR is an effective communication tool used by healthcare professionals to communicate patient information accurately. SBAR stands for Situation, Background, Assessment, and Recommendation. For a better understanding, an example is given below.
SBAR Report from a Nurse to a Health Care Provider
S: "Hello, Dr. Smith. This is Jane, RN, from the Med Surg unit. I am calling to tell you about Ms. White in Room 210, who is experiencing increased pain and redness at her incision site. Her recent...
SBAR Report from a Nurse to a Health Care Provider
S: "Hello, Dr. Smith. This is Jane, RN, from the Med Surg unit. I am calling to tell you about Ms. White in Room 210, who is experiencing increased pain and redness at her incision site. Her recent...
4.8K
01:15Diabetes: Management and Pharmacotherapy
422
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
422
01:06Oral Hypoglycemic Agents: Glinides
280
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
280
01:22Diabetes Mellitus: Type 2 and Gestational
3.0K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
3.0K
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
289
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
289